| Description | Vibostolimab is a monoclonal antibody against T cell immune proteins and the ITIM domain.Vibostolimab has shown anti-tumor activity in in vitro trials and can be used to study non-small cell lung cancer (NSCLC) and melanoma. |
| In vitro | Vibostolimab通过结合TIGIT并阻断TIGIT与其配体(CD112和CD155)之间的相互作用，激活T淋巴细胞，帮助破坏肿瘤细胞[1]。 |
| Synonyms | Vibostolimab (anti-TIGIT) |
| molecular weight | N/A |
| CAS | 2231305-30-7 |
| Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
| References | 1. Niu J, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Ann Oncol. 2022 Feb;33(2):169-180. |